Skip to main content
. 2021 Jun 25;11:695512. doi: 10.3389/fonc.2021.695512

Table 3.

Comparison of the incidence of common adverse events (any grade) between camrelizumab combination and chemotherapy.

Common adverse event Camrelizumab combination (incidence rate) Chemotherapy (incidence rate)
Any grade Any grade
Reactive capillary hyperplasia 78% <1%
Elevated aspartate aminotransferase 47% 33%
Elevated alanine aminotransferase 48% 40%
Anemia 34% 27%
Elevated serum bilirubin 11% 5%
Leukopenia 91% 78%
Hypothyroidism 11% 0%